Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2025
0mins
Should l Buy ?
Source: Newsfilter
Acquisition Completion: GHO Capital and Ampersand have successfully completed the acquisition of Avid Bioservices, a biologics Contract Development and Manufacturing Organisation (CDMO), in an all-cash transaction valued at approximately $1.1 billion, enhancing Avid's growth potential and service offerings.
Future Growth Plans: With the new ownership, Avid aims to leverage additional resources to expand its capabilities and geographic reach, while continuing to support the biotech sector with high-quality development and manufacturing services.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
